TABLE 7

Pharmacokinetics of proprietary compounds in chimpanzees after intravenous administration

Compound
Number
Intravenous Dose
Systemic Clearance (CLs)
Vdss
Half-life i.v. (t1/2)
Bioavailability (F)a
mg/kg l/h/kg l/kg h %
Efavirenzb N.D. N.D. N.D. N.D. N.D. N.D.
DMP 961 N.D. N.D. N.D. N.D. N.D. N.D.
DPC 083 2 1.0 0.016 2.0 89.5 70
DMP 450 4 10.0 0.72 ± 0.15 1.6 ± 0.4 2.6 ± 1.0 24
DMP 851 N.D. N.D. N.D. N.D. N.D. N.D.
DPC 681 N.D. N.D. N.D. N.D. N.D. N.D.
DPC 423c 1 0.08 0.21 2.6 11.3 35
Razaxabanc,d 1 0.07 0.55 2.4 4.4 36
DPC 974 N.D. N.D. N.D. N.D. N.D. N.D.
DPC-A78277 1 0.5 0.090 1.2 9.6 25
DPC 333c 1 0.3 0.40 0.60 1.8 15
DPC R1
1
0.5
1.2
3.7
5.0
23

  • N.D., not determined.

  • ↵ a Mean value calculated using mean oral and i.v. AUC values.

  • ↵ b Also known as DMP 266, L-743,726.

  • ↵ c Dosed as a cassette.

  • ↵ d Also known as DPC 906.